Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors
Open Access
- 6 December 2018
- journal article
- research article
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 36 (1) , 1-6
Abstract
Expression of the ALK gene strongly correlates with the WNT-activated medulloblastomas, which are routinely identified by detection of CTNNB1 mutation. However, some tumors have mutations in other than CTNNB1 genes. Therefore, we investigated if ALK expression may identify WNT-activated tumors without CTNNB1 mutation. In addition, we examined if ALK expression may differentiate WNT-activated medulloblastoma from other malignant posterior fossa tumors. ALK expression was analyzed using immunohistochemistry (clone D5F3) in 70 patients with posterior fossa tumours. Among 55 medulloblastomas, 6 tumors showed ALK expression in > 50% of tumor cells. In one tumor, with ALK positive reaction, negative nuclear reaction against β-catenin and the lack of CTNNB1 mutation, next generation sequencing revealed a presence of pathogenic variant c.3366_3369del in the APC gene, with homozygous deletion leading to inactivation of both copies in tumor cells. MLPA analysis displayed the presence of chromosome 6 monosomy, therefore, confirming the WNT type of this tumor. All analyzed 19 anaplastic ependymomas, 4 choroid plexus carcinomas and 2 atypical teratoid rhabdoid tumors were immunonegative for ALK expression. Therefore, we propose, that immunohistochemical detection of ALK protein should be highly recommended in routine investigation, in parallel to already established methods for identification and differentiation of WNT-activated medulloblastoma.Keywords
Funding Information
- Narodowe Centrum Nauki (2016/21/B/NZ2/01785, 2016/23/B/NZ2/03064)
This publication has 16 references indexed in Scilit:
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumoursJournal of Neuro-Oncology, 2015
- Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical OutcomeJournal of Clinical Oncology, 2011
- Medulloblastoma Comprises Four Distinct Molecular VariantsJournal of Clinical Oncology, 2011
- Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroupsActa Neuropathologica, 2011
- Integrative genomics viewerNature Biotechnology, 2011
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological FeaturesPLOS ONE, 2008
- Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF‐dependent transcription in medulloblastomasInternational Journal of Cancer, 2007
- APC Mutations in Sporadic MedulloblastomasThe American Journal of Pathology, 2000